Chemo plus immunotherapy for resectable bile duct cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of chemotherapy drugs (gemcitabine, cisplatin, nab-paclitaxel) with an immunotherapy (rilvegostomig) before and after surgery for intrahepatic cholangiocarcinoma that can be completely removed. It aims to see if this approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver).
- Your doctor believes the tumor can be completely removed with surgery.
- You have not received any prior chemotherapy, targeted therapy, or immunotherapy for this cancer.
- You are in good general health (ECOG score 0 or 1) and your organs (like kidneys, liver, and blood) function well.
- You are willing to provide a tumor tissue sample for testing.
- You are not pregnant, breastfeeding, and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests giving chemotherapy (cisplatin and gemcitabine) combined with an immunotherapy drug (rilvegostomig) before and after surgery for a type of bile duct cancer called intrahepatic cholangiocarcinoma that has a high risk of coming back. The goal is to see if this combination can reduce the chance of cancer returning.
This trial tests a combination of drugs (durvalumab, cisplatin, and gemcitabine, with or without futibatinib) given before surgery to treat intrahepatic cholangiocarcinoma—a rare cancer of the bile ducts inside the liver. The goal is to shrink the tumor and improve outcomes after surgery.
This trial tests a combination of chemotherapy, immunotherapy (adebrelimab), and a targeted therapy (apatinib) before and after surgery for bile duct cancer that can be removed and has a high risk of coming back. It aims to see if this approach can lower the chance of recurrence.
This trial tests whether giving chemotherapy (gemcitabine and cisplatin) combined with immunotherapy (pembrolizumab) before and after surgery can improve outcomes compared to having surgery right away. It is for people with bile duct cancer that can be removed or is borderline removable.
This trial tests a combination of an immunotherapy (adebrelimab), a targeted therapy (apatinib), and two chemotherapy drugs (gemcitabine and cisplatin) given before surgery for biliary tract cancers that are removable but at high risk of coming back. The goal is to see if this approach helps shrink the tumor and improve outcomes after surgery.
This trial tests a combination of chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (pembrolizumab) given before and after surgery for people with bile duct or gallbladder cancer that can be removed. The goal is to see if this approach helps prevent the cancer from coming back.
Hear when a new Cholangiocarcinoma Resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.